2.11
price down icon10.21%   -0.24
pre-market  Pre-market:  2.20   0.09   +4.27%
loading
Vigil Neuroscience Inc stock is traded at $2.11, with a volume of 156.40K. It is down -10.21% in the last 24 hours and down -22.14% over the past month. Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
See More
Previous Close:
$2.35
Open:
$2.24
24h Volume:
156.40K
Relative Volume:
0.15
Market Cap:
$86.26M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-1.0243
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
-10.21%
1M Performance:
-22.14%
6M Performance:
-42.51%
1Y Performance:
-27.24%
1-Day Range:
Value
$2.06
$2.315
1-Week Range:
Value
$2.06
$2.545
52-Week Range:
Value
$1.49
$6.06

Vigil Neuroscience Inc Stock (VIGL) Company Profile

Name
Name
Vigil Neuroscience Inc
Name
Phone
857-254-4445
Name
Address
100 FORGE ROAD, WATERTOWN
Name
Employee
66
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
VIGL's Discussions on Twitter

Compare VIGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VIGL
Vigil Neuroscience Inc
2.11 86.26M 0 -82.60M -48.61M -2.06
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-24 Initiated William Blair Outperform
Dec-19-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Oct-18-23 Initiated JMP Securities Mkt Outperform
Mar-31-23 Initiated Mizuho Buy
Sep-16-22 Initiated Wedbush Outperform
Aug-29-22 Initiated H.C. Wainwright Buy
Feb-01-22 Initiated Guggenheim Buy
Feb-01-22 Initiated Jefferies Buy
Feb-01-22 Initiated Morgan Stanley Equal-Weight
Feb-01-22 Initiated Stifel Buy
View All

Vigil Neuroscience Inc Stock (VIGL) Latest News

pulisher
02:03 AM

Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks

02:03 AM
pulisher
Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

SPY ETF News, 3/13/2025 - The Globe and Mail

Mar 13, 2025
pulisher
Mar 11, 2025

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Exclusive CNS Forum: Vigil Neuroscience Reveals Latest Breakthroughs in Neurodegeneration Treatment - StockTitan

Mar 11, 2025
pulisher
Mar 06, 2025

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail

Mar 05, 2025
pulisher
Mar 04, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World

Mar 04, 2025
pulisher
Mar 01, 2025

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 20, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire

Feb 20, 2025
pulisher
Feb 17, 2025

What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register

Feb 17, 2025
pulisher
Feb 16, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat

Feb 14, 2025
pulisher
Feb 09, 2025

VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025
pulisher
Feb 06, 2025

VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Are Vigil Neuroscience Inc’shares a good deal? - US Post News

Feb 05, 2025
pulisher
Jan 30, 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan

Jan 30, 2025
pulisher
Jan 27, 2025

Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN

Jan 26, 2025
pulisher
Jan 26, 2025

Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter

Jan 24, 2025
pulisher
Jan 24, 2025

Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa

Jan 24, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia

Jan 23, 2025
pulisher
Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian

Jan 23, 2025
pulisher
Jan 23, 2025

Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan

Jan 23, 2025
pulisher
Jan 22, 2025

Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com

Jan 22, 2025
pulisher
Jan 21, 2025

Suncor Energy: AI-Powered Stock Analysis on Jefferies Valuation Update - The Globe and Mail

Jan 21, 2025

Vigil Neuroscience Inc Stock (VIGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):